期刊文献+

药品(制剂)变更产地研究的关键问题 被引量:1

Key Issues on Study of Drug(Preparation) Production Site Alteration
下载PDF
导出
摘要 目的介绍药品(制剂)变更产地研究的关键问题和一般方法。方法根据笔者在《已上市化学药品变更研究的技术指导原则(一)》起草过程中对产地变更的体会,结合实际工作经验,梳理变更产地研究和技术评价的总体思路,对药品获准上市后制剂产地变更的关键问题进行探讨并举实例说明。结果药品变更产地首先需要注意从安全性、有效性和质量可控性方面对品种进行审查和分析;注意变更产地前后药品处方及制备工艺的一致性、药品质量和疗效的一致性。结论全面和综合评价各类变更对药品质量、安全性、有效性的影响是产地变更研究的基本思路,也是技术审评的基本原则。 Objective To introduce the general method and key issues on the study of drug(preparation) production site alteration.Methods With the author's experience in the process of drafting guidelines for production site alteration and practical work,the general idea for research and technology assessment of the origin change was combed.The key issues of drug(preparation) production site alteration after the drug was approved for market were discussed and explained with specific examples.Results In the first place,it was necessary to study and examine the varieties from aspects of safety,efficacy and quality controllability in the changed origins.Besides,it needed to pay attention to the consistency of drug prescription and preparation process and the consistency of drug quality and efficacy.Conclusion It is a basic idea to comprehensively and synthetically evaluate the influences on drug quality,safety and efficacy exerted by drug production site alteration of all kinds,which is also a basic principle for the technical review and evaluation.
出处 《中国药事》 CAS 2012年第10期1088-1090,1095,共4页 Chinese Pharmaceutical Affairs
关键词 药品(制剂)变更产地 质量控制 安全性 有效性 处方及工艺一致性 drug(preparation) production site alteration quality control safety efficacy consistency of prescription and preparation process
  • 相关文献

参考文献7

  • 1国家食品药品监督管理局.已上市化学药品变更研究的技术指导原则(一)[Z].国食药监注[2008]242号,2008.
  • 2FDA. Guidance for Industry: Immediate Release Solid Oral Dosage Forms. Scale-Up and Postapproval Changes; Chem- istry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation[EB/ OL]. (1995-11 30) [2012-07-02]. www. fda. gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/UCM070636. pdf.
  • 3FDA. Guidance for Industry: SUPACMR, Modified Release Solid Oral Dosage Forms. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation [EB/OL]. (1997-1006) [2012-07-02], www. fda. gov/downloads/Drugs/GuidanceComplianceR egulator yIn formation/Guidances/ UCM070640. pdf.
  • 4FDA. Guidance for Industry: Nonsterile Semisolid Dosage Forms. Scale-Up and Postapproval Changesz Chemistry, Manufacturing, and Controls: In Vitro Release Testing and In Vivo Bioequivalence Documentation [EB/OL]. (1997-06- 13) [2012-07-02]. www. fda. gov/downloads/Drugs/ Guidance Compliance Regulatory Information/ Guidances/ UCM070930 . pdf.
  • 5FDA. Guidance for Industry: SUPAC-IR/MR: Immediate Release and Modified Release Solid Oral Dosage Forms. Manufacturing Equipment Addendum[EB/OL]. (1999 02- 26) [2012-07-02]. www. fda. gov/downloads/I)rugs/ Guidance Compliance Regulatory Information/ Guidances/ UCM070637. pdf.
  • 6FDA. Guidance for Industry: Changes to an Approved NDA or ANDA[EB/OL]. (2004 02-01) [2012 -07-02]. www. fda. gov/downloads/Drugs/Guidance Compliance Regulatory Information/ Guidances/ UCM077097. pdf.
  • 7国家食品药品监督管理局.化学药品注射剂基本技术要求(试行)[Z].国食药监注[2008]7号,2008.

同被引文献7

  • 1国家食品药品监督管理局.药品注册管理办法[EB/OL].2007-07-10[2009-01-12].http://www.sfda.gov.cn/WS01/CL0053/24529.html.
  • 2国家食品药品监督管理局.已上市化学药品变更研究的技术指导原则[EB/OL].http://www.cde.org.cn/zdyz.do?method=largePage&id=2542,2008-06-06/2013-06-09.
  • 3Mtiller L, Mauthe RJ, Riley CM, et al. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity [ J ]. Regul Toxicol Pharmacol, 2006, 44(3) :198-2il.
  • 4国家食品药品监督管理局.化学药物杂质研究技术指导原则[EB/OL].http://www.cde.org.cn/zdyz.d07method=targePage&id=2060,2007-08-23/2013-06-09.
  • 5张宁,于红.化学药品杂质研究思路探析[J].中国新药杂志,2008,17(23):2074-2077. 被引量:21
  • 6杨丽萍,徐蜀远.药品规格设计不合理对临床用药的影响浅析[J].中国药师,2011,14(6):900-901. 被引量:6
  • 7高志峰,张启明.浅谈药品标准管理的思路与实践[J].中国药师,2012,15(10):1515-1516. 被引量:12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部